Literature DB >> 15709883

Novel effects other than antisecretory action and off-label use of proton pump inhibitors.

Hidekazu Suzuki1, Toshifumi Hibi.   

Abstract

The proton pump inhibitors (PPIs) are a relatively new class of agents used for the treatment of acid-related disorders, including peptic ulcer diseases, reflux oesophagitis and Zollinger-Ellison syndrome, and in enhancing antibiotic therapy in the eradication of Helicobacter pylori in patients with peptic ulcer disease. The PPIs are the most potent gastric acid-suppressing agents currently in clinical use. According to the recent basic study, PPIs may act not only as potent acid suppressants, but also as anti-inflammatory or pro-regenerative agents. On the other hand, in the clinical field, general practitioners still tend to prescribe PPIs for unlicensed indications, such as non-ulcer dyspepsia and nonspecific abdominal pain. This article reviews the novel pharmacological action other than acid secretion and the diverse clinical usage of PPIs, in order to seek possible extensions of the use of this unique agent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709883     DOI: 10.1517/14656566.6.1.59

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

1.  A trial of inpatient indication based prescribing during computerized order entry with medications commonly used off-label.

Authors:  S M Walton; W L Galanter; H Rosencranz; D Meltzer; R S Stafford; F Tiryaki; D Sarne
Journal:  Appl Clin Inform       Date:  2011-03-09       Impact factor: 2.342

2.  Acid suppression by proton pump inhibitors enhances aquaporin-4 and KCNQ1 expression in gastric fundic parietal cells in mouse.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Yuriko Minegishi; Etsuko Sugai; Hitoshi Tsugawa; Masato Yasui; Toshifumi Hibi
Journal:  Dig Dis Sci       Date:  2010-05-01       Impact factor: 3.199

3.  Effects of pantoprazole on ulcer healing delay associated with NSAID treatment.

Authors:  Matteo Fornai; Rocchina Colucci; Luca Antonioli; Narcisa Ghisu; Marco Tuccori; Corrado Blandizzi; Mario Del Tacca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-14       Impact factor: 3.000

Review 4.  Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients.

Authors:  Corrado Blandizzi; Marco Tuccori; Rocchina Colucci; Giovanni Gori; Matteo Fornai; Luca Antonioli; Narcisa Ghisu; Mario Del Tacca
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

5.  A new gastroprotective effect of limonoid compounds xyloccensins x and y from xylocarpus molluccensis in rats.

Authors:  Vijai Lakshmi; Vaibhav Mishra; Gautam Palit
Journal:  Nat Prod Bioprospect       Date:  2014-08-03

Review 6.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

7.  Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats.

Authors:  Tae Hwan Kim; Subindra Kazi Thapa; Da Young Lee; Seung Eun Chung; Jun Young Lim; Hyeon Myeong Jeong; Chang Ho Song; Youn-Woong Choi; Sang-Min Cho; Kyu-Yeol Nam; Won-Ho Kang; Soyoung Shin; Beom Soo Shin
Journal:  Pharmaceutics       Date:  2018-09-06       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.